This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The FDA has announced several guidelines and plans to hold at least one public meeting on digital healthtechnologies (DHTs) to be used in drug clinical trials by the end of the year. Drugdevelopment process questions the reliability and accuracy of DHT products. More details at [link]
Digital HealthTechnologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings. Another example is CliniScout Recruit by Healthware – a digital service for recruiting subjects to clinical trials.
The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity.
BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital healthtechnology and develop digital biomarkers for Parkinson’s disease.
Regulatory Landscape: Regulatory Clarity: Clearer regulatory frameworks for digital healthtechnologies will foster investor confidence and higher valuations. However, based on current trends and industry insights, several areas are poised for significant growth and increased valuations: 1.
We’re on a mission to revolutionize drugdevelopment in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights. Beacon’s mobile EEG will join more than a dozen digital healthtechnologies that are already integrated into the Koneksa solution.
We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.”
In 2025, B2C2B models are poised to become increasingly prominent in healthcare, driven by several key factors: Digital Health Boom: The rapid growth of digital healthtechnologies, such as telehealth, wearable devices, and AI-powered diagnostics, is creating new opportunities for B2C2B companies to reach both patients and healthcare providers.
The increasing adoption of digital healthtechnologies, the growing importance of AI and ML, and the evolving regulatory landscape will continue to shape the deal landscape. However, as technology continues to reshape healthcare, we can expect big tech companies to play an increasingly significant role in the years to come.
Blockchain can also ensure the accuracy of the data exchanged among entities, something a HIE (health information exchange) cannot do. Blockchain technology’s potential impact on the life sciences industry (drugdevelopment, distribution and prescribing) is significant.
Goal: Empower individuals to manage their health, prevent diseases, and access healthcare services efficiently. Healthtech Focus: Broader term encompassing the use of technology to improve the overall healthcare delivery system. As we look towards 2030, several key trends are poised to reshape the industry: 1.
2021 has been a historic year for healthcare… and technology has been a crucial piece of the puzzle when it comes to keeping the healthcare industry resilient in the face of the challenges it has seen. . In fact, Exscientia stands by the claim that all drugs in the future will be made using AI. .
With access to these collective resources and by capitalizing on existing biosamples as well as clinical data, including that from digital healthtechnology, researchers will focus on identifying and validating biomarkers and therapeutic targets specific to ALS.
Digital healthtechnologies (DHT) can collect objective, multi-dimensional data passively and remotely with a limited burden for clinical trial participants, providing a way to capture previously inaccessible insights to support drugdevelopment and commercialization.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content